Psychometric and Psychophysiological Actions of Antipsychotics in Men

  • W. Janke
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 55 / 1)


The actions of psychotropic drugs on behavior and accompanying psychophysiological variables vary considerably with various parameters. The most basic parameters are dose level of the drug, administration schedule (single or chronic administration), situational variables (situation in which the drug is given), and patient or subject parameters (personality, initial level of arousal).


Dose Level Antipsychotic Drug Psychotropic Drug Contingent Negative Variation High Dose Level 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Alexander, L.: Effects of psychotropic drugs on conditional responses in man. Neuropsychopharmacology 2, 93–123 (1959)Google Scholar
  2. Bäumler, G.: Beeinflussung der Leistungsmotivation durch Psychopharmaka: I. Die 4 bildthematischen Hauptvariablen. Z. Exp. Angew. Psychol. 22, 1–14 (1975)PubMedGoogle Scholar
  3. Baust, W., Wortmann, J.J., Zimmermann, A.: Untersuchungen zur Beeinflussung kortikaler somatosensorischer Reizantwortpotentiale durch Pharmaka. Arzneim.-Forsch. 27, 440–445 (1977)Google Scholar
  4. Benjamin, F.B., Ikai, K., Clare, H.E.: Effect of proclorperazine on psychologic, psychomotor, and muscular performance. U.S. Armed Forces Med. J. 8, 1433–1440 (1957)PubMedGoogle Scholar
  5. Berger, F.M., Potterfield, J.: The effect of antianxiety tranquilizers on the behavior of normal persons. In: The psychopharmacology of the normal human. Evans, W.O., Kline, N.S. (eds.), 38–113. Springfield: Thomas 1969Google Scholar
  6. Besser, G.M., Duncan, C.: The time course of action in single doses of diazepam, chlorpromazine and some barbiturates as measured by auditory flutter threshold and visual flicker fusion thresholds in man. Br. J. Pharmacol. Chemother. 30, 341–348 (1967)PubMedGoogle Scholar
  7. Besser, G.M., Duncan, C, Quilliam, J.P.: Modification of the auditory flutter fusion threshold by centrally acting drugs in man. Nature 211, 751 (1966)PubMedGoogle Scholar
  8. Boucsein, W., Janke, W.: Experimentalpsychologische Untersuchungen zur Wirkung von Propiramfumarat und Promethazin unter Normal- und Streßbedingungen. Arzneim. Forsch. 24, 675–693 (1974)Google Scholar
  9. Brimer, A., Schnieden, H., Simon, A.: The effect of chlorpromazine and chlordiazepoxide on cognitive functioning. Br. J. Psychiatry 110, 723–725 (1964)PubMedGoogle Scholar
  10. Brodie, CM.: Chlorpromazine as anxiety-reducer: Effects on complex learning and reaction time. J. Exp. Res. Personality 2, 160–167 (1967)Google Scholar
  11. Chessick, R.D., McFarland, R.L., Clark, R.K., Hammer, M., Bassan, M.I.: The effect of morphine, chlorpromazine, pentobarbital and placebo on anxiety. J. Nerv. Ment. Dis. 141, 540–548 (1966)Google Scholar
  12. Cook, L., Davidson, A.B.: Behavioral pharmacology: animal models involving aversive control of behavior. In: Psychopharmacology. Lipton, M.A., DiMascio, A., Killam, K.F. (eds.), 563–568. New York: Raven Press 1978Google Scholar
  13. Cook, L., Sepinwall, J.: Psychopharmacological parameters of emotions. In: Emotions. Levi, L. (ed.). New York: Raven Press 1975Google Scholar
  14. Davis, K.E., Evans, W.O., Gillis, J.S.: The effects of amphetamine and chlorpromazine on cognitive skills and feelings in normal adult males. In: The psychopharmacology of the normal human. Evans, W.O., Kline, N.S. (eds.), 126–161. Springfield: Thomas 1969Google Scholar
  15. Debus, G., Janke, W.: Psychologische Aspekte der Psychopharmakotherapie. In: Handbuch der Psychologic. Pongratz, L.S. (ed.), 2161–2227, Vol. 8/2. Göttingen: Hogrefe 1978Google Scholar
  16. Debus, G., Janke, W.: Methods and methodological considerations in measuring antianxiety effects of tranquilizing drugs. Prog. Neuropsychopharmacol. 3, (1980)Google Scholar
  17. Delay, J., Pichot, P., Nicolas-Charles, D., Peerse, J.: Etude psychométrique des effects de l’amobarbital (amytal) et de la chlorpromazine sur des sujects normeaux. Psychopharmacologia 1, 48–58 (1959)PubMedGoogle Scholar
  18. DiMascio, A., Klerman, G.L., Rinkel, M., Greenblatt, M., Brown, J.: Psycho-physiologic evaluation of phenyltoloxamine, a new phrenotropic agent. Am. J. Psychiatry 115, 301–318 (1958)PubMedGoogle Scholar
  19. DiMascio, A., Havens, L.L., Klerman, G.L.: The psychopharmacology of phenothiazine compounds: A comparative study of the effects of chlorpromazine, promethazine, trifluoperazine and perphenazine in normal males. I: Introduction, aims and methods. J. Nerv. Ment. Dis. 136, 15–28 (1963 a)PubMedGoogle Scholar
  20. DiMascio, A., Havens, L.L., Klerman, G.L.: The psychopharmacology of phenothiazine compounds: A comparative study of the effects of chlorpromazine, promethazine, trifluoperazine, and perphenazine in normal males. II: Results and discussion. J. Nerv. Ment. Dis. 136, 168–186 (1963 b)PubMedGoogle Scholar
  21. Düker, H.: Über reaktive Anspannungssteigerung. Z. Exp. Angew. Psychol. 10, 46–72 (1963)Google Scholar
  22. Dureman, E.I.: Drugs and autonomic conditioning. Stockholm: Almqvist & Wiksell 1959Google Scholar
  23. Evans, W.O., Jewett, A.: The effect of some centrally acting drugs on disjunctive reaction time. Psychopharmacologia 3, 124–127 (1962)PubMedGoogle Scholar
  24. Eysenck, H.J. (ed.): Experiments with drugs. Oxford: Pergamon Press 1963Google Scholar
  25. Fink, M.: EEG and human psychopharmacology. Rev. Pharmacol. 9, 241–259 (1969)Google Scholar
  26. Fink, M.: Psychoactive drugs and the waking EEG, 1966–1976. In: Psychopharmacology. Lipton, M.A., DiMascio, A., Killam, K.F. (eds.), 691–698. New York: Raven Press 1978Google Scholar
  27. Forrest, G.L., Bortner, T.W., Bakker, C.B.: The role of personality variables in response to chlorpromazine, dextroamphetamine and placebo. J. Psychiatr. Res. 5, 281–288 (1967)PubMedGoogle Scholar
  28. Gehring, A., Blaser, P., Spiegel, R., Pöldinger, W.: Bericht über eine pharmakopsychologische Testuntersuchung. Arzneim. Forsch. 21, 15–20 (1971)Google Scholar
  29. Gliedman, L.H., Gantt, W.H.: The effects of reserpine and chlorpromazine on orienting behavior and retention of conditioned reflexes. South. Med. J. 49, 880–883 (1956)PubMedGoogle Scholar
  30. Goldberg, S.C.: Behavioral mechanisms of drug action in schizophrenia. Psychopharmacologia 24, 1–5 (1972)PubMedGoogle Scholar
  31. Graupner, O.K., Kaiman, E.V.: Die Flimmer-Verschmelzungs-Frequenz unter dem Einfluß verschiedener Pharmaka. II: Phenothiazinderivate. Psychopharmacologia 27, 343–347 (1972)PubMedGoogle Scholar
  32. Gupta, B.S.: The effects of stimulant and depressant drugs on verbal conditioning. Br. J. Psychol. 64, 553–557 (1973)PubMedGoogle Scholar
  33. Hawkins, D.R., Pace, R., Pasternack, B., Sandifer, M.G.: A multivariant psychopharmacologic study in normals. Psychosom. Med. 23, 1–17 (1961)PubMedGoogle Scholar
  34. Heimann, H., Reed, C.F., Witt, P.N.: Some observations suggesting preservation of skilled motor acts despite drug-induced stress. Psychopharmacologia 13, 287–298 (1968)PubMedGoogle Scholar
  35. Heninger, G., DiMascio, A., Klerman, G.L.: Personality factors in variability of response to phenothiazines. Am. J. Psychiatry 121, 1091–1094 (1965)PubMedGoogle Scholar
  36. Hoehn-Saric, R., Bacon, E.F., Gross, M.: Effects of chlorpromazine on flicker fusion. J. Nerv. Ment. Dis. 138, 287–292 (1964)PubMedGoogle Scholar
  37. Ideström, CM.: Experimental psychologic methods applied in psychopharmacology. Acta Psychiatr. Neurol. Scand. 35, 302–313 (1960)Google Scholar
  38. Ideström, C.M., Cadenius, B.: Chlordiazepoxide, dipiperon and amobarbital. Dose effect studies on human beings. Psychopharmacologia 4, 235–246 (1963)Google Scholar
  39. Itil, T.M.: Electroencephalography and pharmacopsychiatry. In: Clin. Psychopharmacology. Mod. Probl. Pharmacopsychiatry, Itil, T.M. (ed.), Vol. 1, 163–194. Basel: Karger 1968Google Scholar
  40. Itil, T.M.: Quantitative electroencephalography. In: Psychotropic drugs and the human EEG. Mod. Probl. Pharmacopsychiatr. Vol. 8,. Itil, T.M. (ed.), 43–75. Basel: Karger 1974Google Scholar
  41. Janke, W.: Experimentelle Untersuchungen zur Abhängigkeit der Wirkung psychotroper Substanzen von Persönlichkeitsmerkmalen. Frankfurt: Akademische Verlagsgesellschaft 1964 aGoogle Scholar
  42. Janke, W.: Untersuchungen mit Psychopharmaka als Hilfsmittel der psychologischen Grundlagenforschung. Neuropsychopharmacology 3, 166–169. Amsterdam: Elsevier (1964 b)Google Scholar
  43. Janke, W.: Untersuchungen zur Frage von Wirkungsunterschieden von Fluphenazin nach erstund mehrmaliger Applikation. Psychopharmacologia 7, 349–365 (1965)PubMedGoogle Scholar
  44. Janke, W.: Über psychische Wirkungen verschiedener Tranquilizer bei gesunden, emotional labilen Personen. Psychopharmacologia 8, 340–374 (1966)PubMedGoogle Scholar
  45. Janke, W.: General considerations on the use of performance tests in drug therapy. Psychopharmacologia 26, (Suppl.), 40 (1972)Google Scholar
  46. Janke, W.: Einführung in die Pharmakopsychologie. Stuttgart: Kohlhammer 1979Google Scholar
  47. Janke, W., Debus, G.: Bericht über experimentalpsychologische Untersuchungen über die Wirkung von Methylperidol 5 mg, Chlordiazepoxyd 10 mg, Meprobamat 400 mg, Promazin 25 mg und Placebo auf gesunde Personen. Marburg: Institut für Psychologie 1962Google Scholar
  48. Janke, W., Debus, G.: Experimental studies on antianxiety agents with normal subjects: Methodological considerations and review of the main effects. In: Psychopharmacology: a review of progress 1957–1967. 205–230. Efron, D.H. (ed.). Washington: U.S. Government Printing Office 1968Google Scholar
  49. Janke, W., Debus, G.: Double-blind psychometric evaluation of pimozide and haloperidol versus placebo in emotionally labile volunteers under two different work load conditions. Pharmakopsychiatr. Neuropsychopharmakol. 5, 34–51 (1972)Google Scholar
  50. Janke, W., Debus, G.: Pharmakopsychologische Untersuchungen an gesunden Probanden zur Prognose der therapeutischen Effizienz von Psychopharmaka. Arzneim. Forsch. 25, 1185–1195(1975)Google Scholar
  51. Janke, W., Debus, G.: Die Eigenschaftswörterliste. Göttingen: Hogrefe 1978Google Scholar
  52. Janke, W., Debus, G., Longo, N.: Differential psychopharmacology of tranquilizing and sedating drugs. In: Differential psychopharmacology of anxiolytics and sedatives. Mod. Probl. Pharmacopsychiatr. Boissier, J.R. (ed.), Vol. 14, 13–98. Basel: Karger 1979Google Scholar
  53. Kelly, E.L., Miller, J.G., Marquis, D.G., Gerard, R.W., Uhr, L.: Personality differences and continued meprobamate and proclorperazine administration. Arch. Neurol. Psychiatry 80, 241–252 (1958)Google Scholar
  54. Kopell, B.S., Wittner, W.K.: The effects of chlorpromazine and methamphetamine on visual signal-from-noise detection. J. Nerv. Ment. Dis. 147, 418–424 (1968)PubMedGoogle Scholar
  55. Kornetsky, C., Humphries, O.: Psychological effects of centrally acting drugs in man: Effects of chlorpromazine and secobarbital on visual and motor behavior. J. Ment. Sci. 104, 1093–1099 (1958)PubMedGoogle Scholar
  56. Kornetsky, C, Humphries, O., Evarts, E.V.: Comparison of psychological effects of certain centrally acting drugs in man. Arch. Neurol. Psychiatr. 77, 318–324 (1957)Google Scholar
  57. Kornetsky, C, Orzack, M.H.: A research note on some of the critical factors on the dissimilar effects of chlorpromazine and secobarbital on the digit symbol substitution and continuous performance tests. Psychopharmacologia 6, 79–86 (1964)PubMedGoogle Scholar
  58. Kornetsky, C., Vates, T.S., Kessler, E.K.: A comparison of hypnotic and residual psychological effects of single doses of chlorpromazine and secobarbital in man. J. Pharmacol. Exp. Ther. 127, 51–54 (1959)PubMedGoogle Scholar
  59. Lader, M.H.: Psychophysiological aspects of psychopharmacology. In: Neuropsychopharmacology 168–175. Boissier, J.R., Hippius, H., Pichot, P. (eds.). Amsterdam: Excerpta Medica 1975Google Scholar
  60. Lader, M.H., Wing, L.: Physiological measures, sedative drugs, and morbide anxiety. Oxford: University Press 1966Google Scholar
  61. Lehmann, H.E., Ban, T.A.: Effects of psychoactive drugs on conflict avoidance behavior in human subjects. Activitas Nervosa Superior 13, 82–85 (1971)PubMedGoogle Scholar
  62. Lehmann, H.E., Csank, J.: Differential screening of phrenotropic agents in man: Psychophysiologic test data. J. Clin. Exp. Psychopathol. 18, 222–235 (1957)PubMedGoogle Scholar
  63. Lennard, H.L., Epstein, L.J., Katzung, B.G.: Psychoactive drug action and group interaction process. J. Nerv. Ment. Dis. 145, 69–78 (1967)PubMedGoogle Scholar
  64. Lewrenz, H., Kempe, P.: Psychologische Untersuchungen nach Dogmatil-Applikation. Münch. Med. Wochenschr. 116, 583–584 (1974)Google Scholar
  65. Liljequist, R., Linnoila, M., Mattila, M.J., Saario, L, Seppälä, T.: Effect of two weeks’ treatment-with thioridazine, chlorpromazine, sulpiride and bromazepam, alone or in combination with alcohol, on learning and memory in man. Psychopharmacologia 44, 205–208 (1975)PubMedGoogle Scholar
  66. Lind, N.A., Turner, P.: The effect of chlordiazepoxide and fluphenazine on critical flicker frequency. J. Pharm. Pharmacol. 20, 804 (1968)PubMedGoogle Scholar
  67. Loeb, M., Hawkes, G.R., Evans, W.O., Alluisi, E.A.: The influence of d-amphetamine, benactyzine, and chlorpromazine on performance in an auditory vigilance task. Psychon. Sci. 3, 29–30 (1965)Google Scholar
  68. Loomis, T.A., West, T.C.: Comparative sedative effects of a barbiturate and some tranquilizer drugs on normal subjects. Pharmacol. Exp. Ther. 122, 525–531 (1958)Google Scholar
  69. Malitz, S., Kanzler, M.: Effects of drugs on perception in man. Res. Publ. Ass. Nerv. Ment. Dis. 48, 35–53 (1970)Google Scholar
  70. McNair, D.M.: Antianxiety drugs and human performance. Arch. Gen. Psychiatry 29, 611–617 (1973)PubMedGoogle Scholar
  71. McPeake, J.D., DiMascio, A.: Drug-personality interaction in the learning of a nonsense syllable task. Psychol. Rep. 15, 405–406 (1964)Google Scholar
  72. McPeake, J.D., DiMascio, A.: Drug personality interaction in the learning of a nonsense syllable task. J. Psychiatr. Res. 3, 105–111 (1965)PubMedGoogle Scholar
  73. Milner, G., Landauer, A.A.: Alcohol, thioridazine and chlorpromazine effects on skills related to driving behavior. Br. J. Psychiatry 118, 351–352 (1971)PubMedGoogle Scholar
  74. Mirsky, A., Kornetsky, C.: On the dissimilar effects of drugs on the digit symbol substitution and continuous performance tests. Psychopharmacologia 5, 161–177 (1964)PubMedGoogle Scholar
  75. Mirsky, A., Primac, D.W., Bates, R.: The effects of chlorpromazine and secobarbital on the C.P.T. J. Nerv. Ment. Dis. 128, 12–17 (1959)PubMedGoogle Scholar
  76. Nakra, B.R.S., Bond, A.J., Lader, M.H.: Comparative psychotropic effects of metoclopramide and prochlorperazine in normal subjects. J. Clin. Pharmacol. 15, 449–454 (1975)PubMedGoogle Scholar
  77. Pöldinger, W.: Vergleichende Untersuchungen antidepressiv wirkender Psychopharmaka an gesunden Versuchspersonen. Neuropsychopharmakologie 4, 416–420 (1965)Google Scholar
  78. Rappaport, M., Hopkins, H.K.: Signal detection and chlorpromazine. Hum. Factors 13, 387–390 (1971)PubMedGoogle Scholar
  79. Rappaport, M., Hopkins, H.K., Silverman, J., Hall, K.: Auditory signal detection in schizophrenics. Psychopharmacologia 24, 6–28 (1972)PubMedGoogle Scholar
  80. Rickeis, K. (Ed.): Nonspecific factors in drug therapy. Springfield: Thomas 1968Google Scholar
  81. Rickels, K., Weise, C.C., Clark, E.L., Wheeler, B., Rose, C.K., Rosenfeld, H., Gordon, P.E.: Thiothixene and thioridazine in anxiety. Br. J. Psychiatry 125, 79–87 (1974)PubMedGoogle Scholar
  82. Robinson, D.N., Sabat, S.R.: Sensory psychopharmacology. In: Current development in psychopharmacology. Essman, W.B., Valzelli, L. (eds.), Vol. 2, 185–204. New York: Wiley 1975Google Scholar
  83. Rossvold, H.E., Mirsky, A.F., Sarason, I., Bransome, E.B., Beck, L.H.: A continuous performance test of brain damage. J. Consult. Psychol. 20, 343–350 (1956)Google Scholar
  84. Roubicek, M., Major, I.: EEG profile and behavioral changes after a single dose of clozapine in normals and schizophrenics. Biol. Psychiatry 12, 613–633 (1977)PubMedGoogle Scholar
  85. Roubicek, J., Matejcek, M., Porsolt, R.: Computer analysed EEG and behavioral changes after psychoactive drugs. Int. J. Neurol. 10, 33–40 (1975)PubMedGoogle Scholar
  86. Saletu, B.: Classification of psychotropic drugs based on human evoked potentials. In: Mod. Probl. Pharmacopsychiatr., Vol.8. Psychotropic drugs and the human EEG. Itil, T.M. (ed.), 258–285. Basel: Karger 1974Google Scholar
  87. Saletu, B.: Psychopharmaka, Gehirntätigkeit und Schlaf. München: Karger 1976Google Scholar
  88. Schäfer-Plog, U.: Die Wirkung von Fluphenazin auf das Testverhalten von Versuchspersonen unter Berücksichtigung der vegetativen Labilität und des Einflusses des Versuchsleiters. Arzneim. Forsch. 18, 443–447 (1968)Google Scholar
  89. Schneider, R.A., Costiloe, J.P.: Effect of centrally active drugs on conditioning in man: The inhibiting and facilitating effects of chlorpromazine, amobarbital and methylphenidylacetate on the conditioned galvanic skin response. Am. J. Med. Sci. 233, 418–423 (1957)PubMedGoogle Scholar
  90. Scholander, T.: The effects of amphetamine and chlorpromazine on the habituation of autonomic response elements. Ann. Acad. Reg. Scient. Upsaliensis 5, 35–62 (1961)Google Scholar
  91. Serafetinides, E.A., Clark, M.L.: Psychological effects of single-dose antipsychotic medication. Biol. Psychiatry 7, 263–267 (1973)PubMedGoogle Scholar
  92. Shurtleff, D., Mostofsky, D., DiMascio, A.: The effects of some phenothiazine derivates on the discrimination of auditory clicks. Psychopharmacologia 3, 153–165 (1962)PubMedGoogle Scholar
  93. Sloane, R.B., Payne, R.W., Willett, R.A.: The effect of thioridazine on autonomic conditioning and arousal in normal subjects. Int. Pharmacopsychiatry 2, 206–214 (1969)Google Scholar
  94. Smith, J.M., Misiak, H.: Critical flicker frequency (CFF) and psychotropic drugs in normal human subjects: A review. Psychopharmacology 47, 175–182 (1976)Google Scholar
  95. Stone, G.C., Callaway, E., Jones, R.T., Gentry, T.: Chlorpromazine slows decay of visual short-term memory. Psychon. Sci. 16, 229–230 (1969)Google Scholar
  96. Tecce, J.J., Cole, J.O.: Psychophysiologic responses of schizophrenics to drugs. Psychopharmacologia 24, 159–200 (1972)PubMedGoogle Scholar
  97. Tecce, J.J., Cole, J.O., Savignano-Bowman, J.: Chlorpromazine effects on brain activity (contingent negative variation) and reaction time in normal women. Psychopharmacologia 43, 293–295 (1975)PubMedGoogle Scholar
  98. Tecce, J.J., Savignano-Bowman, J., Cole, J.O.: Drug effects on contingent negative variation and eyeblinks. In: Psychopharmacology. Lipton, M.A., DiMascio, A., Killam, K.F. (eds.), 745–758. New York: Raven Press 1978Google Scholar
  99. Turner, P.: A comparison of fluphenazine and chlorpromazine on critical flicker fusion frequency. J. Pharm. Pharmacol. 18, 836 (1966)PubMedGoogle Scholar
  100. Uhr, L., Platz, A., Miller, J.G.: A pilot experiment on the effects of meprobamate and of prochlorperazine on tests of cognition and perception. Percep. Mot. Skills 11, 90 (1960)Google Scholar
  101. Uhr, L., Clay, M., Platz, A., Miller, J.G., Kelly, E.L.: Effects of meprobamate and of prochlorperazine on positive and negative conditioning. J. Abnorm. Soc. Psychol. 63, 546–551 (1961)PubMedGoogle Scholar
  102. Vincent, H.B.: The effect of largactil on Rorschach test results. Diss. Halifax: Dalhousie Univers. 1955Google Scholar
  103. Wenzel, D.G., Rutledge, C.: Effects of centrally acting drugs on human motor and psychomotor performance. J. Pharmac. Sci. 51, 631–644 (1962)Google Scholar
  104. Zirkle, G.A., King, P.D., McAtee, O.B., v. Dyke, R.: Effects of chlorpromazine and alcohol on coordination and judgment. J.A.M.A. 14, 1496–1499 (1959)Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1980

Authors and Affiliations

  • W. Janke

There are no affiliations available

Personalised recommendations